DDInter915 DDInter1398
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Indacaterol {u} (Compound) causes {v} (Side Effect) Nasopharyngitis
Nasopharyngitis {u} (Side Effect) is caused by {v} (Compound) Pasireotide
Indacaterol {u} (Compound) causes {v} (Side Effect) Nasopharyngitis
Nasopharyngitis {u} (Side Effect) is caused by {v} (Compound) Octreotide
Octreotide {u} (Compound) resembles {v} (Compound) Pasireotide
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Indacaterol {u} (Compound) causes {v} (Side Effect) Nasopharyngitis
Nasopharyngitis {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pasireotide
Indacaterol {u} (Compound) causes {v} (Side Effect) Diabetes mellitus
Diabetes mellitus {u} (Side Effect) is caused by {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pasireotide
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Isoprenaline
Isoprenaline {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Indacaterol {u} (Compound) causes {v} (Side Effect) Diabetes mellitus
Diabetes mellitus {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Linagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Indacaterol (Compound) causes Nasopharyngitis (Side Effect) and Nasopharyngitis (Side Effect) is caused by Pasireotide (Compound)
Indacaterol (Compound) causes Nasopharyngitis (Side Effect) and Nasopharyngitis (Side Effect) is caused by Octreotide (Compound) and Octreotide (Compound) resembles Pasireotide (Compound)
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Indacaterol (Compound) causes Nasopharyngitis (Side Effect) and Nasopharyngitis (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Indacaterol (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Indacaterol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Pasireotide
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Isoprenaline (Compound) and Isoprenaline may lead to a major life threatening interaction when taken with Pasireotide
Indacaterol (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Linagliptin (Compound) and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide